Overview

Biomarker Study in Participants With Migraine

Status:
Completed
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
This is a study of participants with a diagnosis of migraine who completed another clinical trial NCT02163993. The participants received either LY2951742 or placebo. This study NCT02766517 will evaluate how certain biomarkers may be related to the participant's response in study NCT02163993. The study will last about five days.
Phase:
Early Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Capsaicin